AstraZeneca Plc

TOKYO (Reuters) - Asian shares deepened losses on Thursday after Federal Reserve Chairman Ben Bernanke confirmed market fears that the Fed would begin reducing its stimulus later this year as the economy improved. Sentiment was also fragile ahead of an...

Following is a summary of current science news briefs. With Russian help, Europe prepares to search for life on Mars PARIS (Reuters) - The European Space Agency signed final contracts with Thales Alenia Space Italy for work on a pair of missions to...

Following is a summary of current health news briefs. Analysis: Hospital investors sold on U.S. health reform despite bumps CHICAGO (Reuters) - Shares of U.S. hospital operators have been on a tear this year, on average posting triple the gains of the...

LONDON, June 19 (Reuters) - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study. The companies, which jointly sell several diabetes drugs, said on Wednesday the so-called SAVOR trial...

LONDON (Reuters) - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study, disappointing investors who had thought it might demonstrate an edge over rivals. The companies, which jointly sell...

LONDRES, 19 jun (Reuters) - El medicamento de AstraZeneca y Bristol-Myers Squibb para la diabetes Onglyza no logró reducir los riesgos cardíacos en un importante estudio clínico, decepcionando a inversores que habían pensado que demostraría una...

LONDON, June 18 (Reuters) - AstraZeneca has chosen a science park in Cambridge, England, next to the world-renowned Addenbrooke's Hospital, as its new $500 million global headquarters and centre of drug research. Property industry sources told Reuters...

LONDON (Reuters) - AstraZeneca has chosen a science park on the southern outskirts of Cambridge, England, next to the world-renowned Addenbrooke's Hospital, for its new $500 million global headquarters and research center. Property industry sources...

LONDON (Reuters) - Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday. Speaking as the group unveiled...

LONDON, June 17 (Reuters) - AstraZeneca PLC : * Medimmune,NGM Biopharmaceuticals announce agreement to discover and develop therapies for diabetes and obesity * MedImmune,NGM will jointly advance peptide and antibody drug candidates based on...

LONDON (Reuters) - British drugmaker AstraZeneca is deepening its collaboration with academia by roping in more outside researchers to help to find new cancer drugs. Scientists at the Cancer Research UK Paterson Institute for Cancer Research at the...

By Bill Berkrot NEW YORK, June 12 (Reuters) - Global drugmakers said on Wednesday they would cooperate with an independent review to address concerns of a potential link between widely used diabetes medicines and pancreatic cancer and other safety...